Thomas Denize

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 11

Top Topics

Renal Cell Carcinoma

Prognostic Factors

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Proceedings of the National Academy of Sciences of the United States of America

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Denize, Opeyemi A Jagede, Sayed Matar, Nourhan El Ahmar, Destiny J West, Emily Walton, Aseman Sheshdeh Bagheri, Varunika Savla, Yasmin Nabil Laimon, Saurabh Gupta, Sai Vikram Vemula, David A Braun, Kelly P Burke, Paul J Catalano, Gordon J Freeman, Robert J Motzer, Michael B Atkins, David F McDermott, Arlene H Sharpe, Toni K Choueiri, Sabina Signoretti
PD-1 Expression on Intratumoral Regulatory T Cells is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear Cell Renal Cell Carcinoma Patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Thomas Denize, Catherine B Meador, Anna B Rider, Maria L Ganci, Jaimie L Barth, Marina Kem, Mari A Mino-Kenudson, Yin Pun Hung
Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma. Histopathology (2023)
Renee Maria Saliby, Amin H Nassar, Ziad Bakouny, Valisha Shah, Wanling Xie, Ronan Flippot, Thomas Denize, M Harry Kane, Katrine N Madsen, Miriam Ficial, Laure Hirsch, Xiao X Wei, John A Steinarter, Lauren C Harshman, Ulka N Vaishampayan, Mariano Severgnini, David F McDermott, Gwo-Shu Mary Lee, Wenxin Xu, Eliezer Van Allen, Bradley Alexander McGregor, Sabina Signoretti, Toni K Choueiri, Rana R McKay, David A Braun
Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma. Cancer immunology research (2023)
Thomas Denize, Yue Hou, Jean-Christophe Pignon, Emily Walton, Destiny J West, Gordon J Freeman, David A Braun, Catherine J Wu, Saurabh Gupta, Robert J Motzer, Michael B Atkins, David McDermott, Toni K Choueiri, Sachet A Shukla, Sabina Signoretti
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (18) (2022)
Thomas Denize, Subrina Farah, Alessia Cimadamore, Abdallah Flaifel, Emily Walton, Maura A Sticco-Ivins, Chris Labaki, David A Braun, Maxine Sun, Evelyn Wang, Wanling Xie, Toni K Choueiri, Sabina Signoretti
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (4) (2022)
Michael B Atkins, Opeyemi A Jagede, Naomi B Haas, David F McDermott, Mehmet A Bilen, Mark N Stein, Jeffrey A Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael E Hurwitz, David J Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, Catherine J Wu, David A Braun, David J Einstein, Paul J Catalano, Hans Hammers
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (25) (2022)
Thomas Denize, Simona Massa, Alexander Valent, Lucia Militti, Alessia Bertolotti, Marta Barisella, Nathalie Rioux-Leclercq, Gabriel G Malouf, Filippo Spreafico, Arnauld Verschuur, Justine van der Beek, Lieve Tytgat, Marry M van den Heuvel-Eibrink, Gordan M Vujanic, Paola Collini, Aurore Coulomb
Renal cell carcinoma in children and adolescents: a retrospective study of a French-Italian series of 93 cases. Histopathology 80 (6) (2022)
Laura A Stransky, Sean M Vigeant, Bofu Huang, Destiny West, Thomas Denize, Emily Walton, Sabina Signoretti, William G Kaelin
Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. Proceedings of the National Academy of Sciences of the United States of America 119 (14) (2022)
Eliana Marostica, Rebecca Barber, Thomas Denize, Isaac S Kohane, Sabina Signoretti, Jeffrey A Golden, Kun-Hsing Yu
Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (10) (2021)
Simon Garinet, Audrey Didelot, Thomas Denize, Alexandre Perrier, Guillaume Beinse, Jean-Baptiste Leclere, Jean-Baptiste Oudart, Laure Gibault, Cecile Badoual, Françoise Le Pimpec-Barthes, Pierre Laurent-Puig, Antoine Legras, Helene Blons
Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC. British journal of cancer 125 (11) (2021)
Thomas Denize, Pierre Alexandre Just, Mathilde Sibony, Hélène Blons, Marc Olivier Timsit, Tom Drossart, Deborah Jakubowicz, Chloé Broudin, Aurélien Morini, Thierry Molina, Yann Vano, Marie Auvray-Kuentz, Stéphane Richard, Arnaud Mejean, Anne-Paule Gimenez-Roqueplo, Nelly Burnichon, Virginie Verkarre
MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 34 (3) (2020)